The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease

Internal Medicine

Volumn 42, Issue 8, 2003, Pages 670-675

  Kobashi, Yoshihiro ^a   Matsushima, Toshiharu ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Clinical effect; Combined chemotherapy; Guideline of ATS and JST; MAC pulmonary disease

Indexed keywords

CLARITHROMYCIN; CORTICOSTEROID; ETHAMBUTOL; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PRACTICE GUIDELINE; PROGNOSIS; PROSPECTIVE STUDY; RASH; SPUTUM ANALYSIS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VERTIGO; VISUAL DISORDER;

EID: 0042035673     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.670     Document Type: Article

References (19)

1. Sakatani M. Nontuberculous mycobacteriosis (NTM) in Japan-epidemiologic and clinical study. Kekkaku 69: 119-124, 1994.
2. Tsukamura M, Shimoide H, Kita N, Kondo H, Segawa J. Clinical picture of lung disease due to Mycobacterium avium-intracellulare complex. Kekkaku 51: 41-46, 1976.
3. Hunter AM, Campbell IA, Jenkins PA, Smith AP. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax 36: 326-329, 1981.
4. Ahn CH, Ahn SS, Anderson RA, Murphy DT, Mammo A. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 134: 438-441, 1986.
5. Etzkorn ET, Aldarondo S, McAllister CK, Matthews J, Ognibene AJ. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis 134: 442-445, 1986.
6. Horsburgh CR, Mason UG, Heifets LB, Southwick K, Labrecque J, Iseman MD. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 135: 418-421, 1987.
7. Wallace RJ, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung diseas. Am J Respir Crit Care Med 149: 1335-1341, 1994.
8. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP, Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 107: 1035-1040, 1995.
9. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT, Wallace RJ Jr. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 153: 1766-1772, 1996.
10. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 156: S1-S25, 1997.
11. Opinions of Japanese Society for Tuberculosis committee on therapy of atypical mycobacterium infections. Kekkaku 73: 599-605, 1998.
12. Daniel WW Biostatics. A Foundation for Analysis in the Health Sciences, 5th ed. John Wiley & Sons, Tronto, 1991.
13. Wallace RJ, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 16: 215-221, 1993.
14. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarthromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 160: 866-872, 1999.
15. Wallace RJ, Zhang Y, Brown BA, et al. Polyclonal Mycobacyetium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 158: 1235-1244, 1998.
16. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randamized, open-label trial of azithromycin plus etambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 27: 1278-1285, 1998.
17. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321: 863-868, 1989.
18. Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Saf 11: 242-251, 1994.
19. Sato K, Ebe T. A study on the effect of combined chemotherapy on Mycobacterium avium complex pulmonary disease. Kekkaku 75: 471-476, 2000.